The Sabin Vaccine Institute Board of Trustees oversees the activities of the organization and our various programs. We are grateful for the activism and generosity of our Board of Trustees, composed of international leaders in business, civil service, academia and philanthropy.
Axel Hoos, M.D., Ph.D.
|Peter J. Hotez, M.D., Ph.D.|
Ex Officio Trustee
President and Director, Sabin Product
Development Partnership (PDP)
Philip K. Russell, M.D.
Peter L. Thoren
Michael E. Whitham
H. R. Shepherd, D.Sc.
Axel Hoos, M.D., Ph.D. is Senior Vice President, Oncology R&D at GlaxoSmithKline (GSK), where he is responsible for the Oncology Therapy Area and building GSK’s immuno-oncology portfolio. Previously, Dr. Hoos was the Medical Lead for Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipilimumab; anti CTLA-4), a breakthrough medicine, and the first successful therapy in the field of Immuno-Oncology. Before BMS, Dr. Hoos was Senior Director of Clinical Development at Antigenics Inc., a biotechnology company, which develops therapies for cancer and infectious diseases.
In addition to serving as a Sabin Trustee, Dr. Hoos also serves as co-director of the Cancer Immunotherapy Consortium (CIC) of the New York City-based Cancer Research Institute (CRI) and a Board member of the Germany-based Association for Cancer Immunotherapy (CIMT), both organizations advancing the science and development of immune therapies against malignant diseases.
Dr. Hoos has a special interest in fostering scientific and methodological innovation and is a strong advocate of collaborative initiatives to improve drug development and global health. Through his leadership a new paradigm for the development of cancer immunotherapies has been defined, which helped launch of the field of Immuno-Oncology in 2011.
Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD from the German Cancer Research Center (DKFZ) both in Heidelberg, Germany. He trained at the Technical University in Munich, Germany and at Memorial Sloan-Kettering Cancer Center in New York City. He is an alumnus of the Executive Leadership Program at Harvard Business School.
Chief Executive Officer
Amy Finan was appointed as the Chief Executive Officer of the Sabin Vaccine Institute on April 18, 2016.
Prior to joining Sabin, Ms. Finan served as senior vice president responsible for business development at the Biotechnology Innovation Organization (BIO), the world's largest membership organization representing biotechnology companies, academic institutions and state biotechnology centers.
During her 11-year tenure at BIO, Ms. Finan played a critical role in expanding the organization’s membership and revenue base and implementing innovative approaches to fundraising, branding, marketing and programming. In 2011 and simultaneous with her BIO responsibilities, she also served as president of the Biotechnology Institute, an organization founded by BIO in 1998 to promote life science education.
Prior to BIO, Ms. Finan led corporate communications and investor relations for the former clinical-stage biotechnology company EntreMed Inc. Between 1999 and 2001, she created and implemented the biotech initiative of Montgomery County, Maryland, which included economic development policies, incubator programs, legislative packages and communication plans. Ms. Finan began her biotechnology career as a government relations director for the National Association of Biomedical Research.
Ms. Finan studied at the London School of Economics & Political Science and graduated with a bachelor’s degree in political science from Trinity College in Washington, D.C.
Peter Hotez, MD, PhD is President of the Sabin Vaccine Institute and leads the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development based at the Baylor College of Medicine in Houston, Texas. He is the Texas Children’s Hospital Endowed Chair of Tropical Pediatrics and serves as Chief of the Section of Pediatric Tropical Medicine, Professor of Pediatrics and Molecular Virology & Microbiology and the founding Dean of the new National School of Tropical Medicine at Baylor College of Medicine. His academic research focuses on vaccine development for a wide range of neglected tropical diseases around the globe, as well as studies to increase awareness about the neglected tropical diseases in developing countries and in the United States.
Dr. Hotez created the Sabin Vaccine Institute Product Development Partnership (PDP), which includes the Human Hookworm Vaccine Initiative, the Schistosomiasis Vaccine Initiative and newer efforts to develop vaccines for Chagas disease, leishmaniasis and SARS. In addition, Dr. Hotez was instrumental in creating the Global Network for Neglected Tropical Diseases, an innovative partnership dedicated to controlling the spread of neglected tropical diseases (NTDs) in developing nations.
Dr. Hotez graduated Phi Beta Kappa from Yale University in1980 with a degree in Molecular Biophysics and Biochemistry and obtained both his MD and PhD from the medical scientist-training program at Weill Cornell Medical College and The Rockefeller University in New York.
Dr. Hotez serves as immediate past President of the American Society of Tropical Medicine and Hygiene and Editor-in-Chief of PLoS Neglected Tropical Diseases. He has served in membership or leadership roles with a multitude of professional organizations, including as a current member of the NIH Council of Councils Committee. He is a member of the Institute of Medicine of the National Academy of Sciences.
Kenneth Kelley, M.B.A., is currently a Harvard Advanced Leadership Fellow, focusing on global health, biosecurity and the market inefficiency leading to a lack of vaccines against neglected tropical diseases (NTDs) and emerging pandemic threats. He co-founded PaxVax, a specialized vaccine company, in 2007, and served as its chief executive officer from 2008 to May 2015. He has more than 30 years of entrepreneurial, venture capital, operational and technical biotechnology experience. He serves on the board of directors of several private and public biotech companies.
Paul Maddon is a biotechnology entrepreneur and private investor with over 25 years of industry experience. He is the founder of Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), the first biotechnology company to emerge from Columbia University, and he currently serves as the company’s Director and Vice Chairman of the Board of Trustees. During his tenure at Progenics, Paul developed innovative therapeutic products in the fields of gastroenterology, oncology, and infectious diseases. As Chief Science Officer, Paul was responsible for preclinical and clinical development of the Company’s major therapeutic products, including RELISTOR ®. RELISTOR ® was approved in 2008 in the U.S. and E.U. and is now marketed in over 50 countries for the treatment of opioid-induced constipation in patients with advanced illness.
Prior to founding Progenics, from 1981 to 1988, Paul performed research at the Howard Hughes Medical Institute at Columbia University where in a series of landmark studies, he isolated the gene encoding CD4 and demonstrated that CD4 serves as the primary receptor for entry of the AIDS virus (HIV) into immune system. In addition, Paul has a long-standing commitment to science education and to providing research opportunities for students. At Columbia University, Paul received a B.A. in Biochemistry, an M.D. from the College of Physicians and Surgeons and a Ph.D. in Biochemistry and Molecular Biophysics from the Graduate School of Arts and Sciences.
Jordan S. Orange, M.D., Ph.D., is the chief of Immunology, Allergy and Rheumatology, and professor and section head for Immunology, Allergy and Rheumatology in the department of Pediatrics at Baylor College of Medicine. He also serves as the director of the Center for Human Immunobiology at Texas Children’s Hospital. Dr. Orange is a board-certified pediatrician with a clinical specialty in primary immunodeficiency disease. Dr. Orange has focused his research efforts on primary immunodeficiency diseases and human natural killer cell deficiencies.
Michael Posner is a Professor of Business and Society at NYU’s Stern School of Business, where he is working to launch the first-ever center on business and human rights at a business school. Prior to joining NYU Stern, Michael served from 2009 to 2013 in the Obama Administration as Assistant Secretary of State for the Bureau of Democracy, Human Rights and Labor at the State Department. From 1978 to 2009, he led Human Rights First, a New York-based human rights advocacy organization.
Michael played a major role in shaping U.S. policy from inside and outside of government on issues ranging from refugee and asylum law and policy, national security and human rights, Internet freedom, and business and human rights. Throughout his career, he has been active in several leading organizations in the field of business and human rights, including the Fair Labor Association, the Global Network Initiative, and the Voluntary Principles on Security and Human Rights.
Before joining Human Rights First, Posner was a lawyer with Sonnenschein, Nath & Rosenthal in Chicago. He lectured at Yale Law School from 1981 to 1984, and again in 2009. He was a visiting lecturer at Columbia University Law School from 1984 to 2008. A member of the California Bar and the Illinois Bar, he received his J.D. from the University of California, Berkeley Law School (Boalt Hall) in 1975, and a B.A. with distinction and honors in History from the University of Michigan in 1972. Posner resides with his family in New York City.
Regina Rabinovich is the ExxonMobil Malaria Scholar in Residence at Harvard University. She has over 25 years of experience in global health across research, public health and philanthropic sectors, with focus on strategy, global health product development and the introduction and scale-up of tools and strategies resulting in impact on endemic populations.
From 2003-2012, Dr. Rabinovich served as Director of the Infectious Diseases division at the Bill & Melinda Gates Foundation, overseeing the development and implementation of strategies for the prevention, treatment and control of infectious diseases of particular relevance to malaria, pneumonia, diarrhea and neglected infectious diseases. Dr. Rabinovich has served in Chief of the Clinical and Regulatory Affairs Branch at the US National Institute of Allergy and Infectious Diseases (NIAID), focusing on the development and evaluation of vaccines through a network of US clinical research units. She participated in the Children's Vaccine Initiative, a global effort to prevent infectious diseases in children in the developing world.
In 1999, Dr. Rabinovich became director of the PATH Malaria Vaccine Initiative, a project funded by the Bill & Melinda Gates Foundation to advance efforts to develop promising malaria vaccine candidates. She serves on the boards of AERAS, a non-profit biotech focused on development of vaccines for tuberculosis, and the Catholic Medical Mission Board.
Dr. Rabinovich holds a medical degree from Southern Illinois University and a Masters of Public Health degree from the University of North Carolina.
Retired Major General Philip K. Russell, M.D. served in the U.S. Army Medical Corps from 1959 to 1990, pursuing a career in infectious disease and tropical medicine research.
Following his training in internal medicine, he assumed a succession of research assignments at the Walter Reed Army Institute of Research and overseas laboratories in Pakistan, Thailand, and Vietnam. He conducted laboratory and clinical research on a variety of viral and parasitic infectious diseases, including dengue, malaria, hepatitis, and respiratory viruses.
Russell has authored or co-authored more than 100 research publications and contributed to the successful development of several vaccines important to the military and public health, including those of adenovirus, meningitis, and hepatitis A and B. Later, as director of the Walter Reed Army Institute of Research, he led research on vaccines against dengue and malaria. As commander of the U.S. Army Medical Research and Development Command, he spearheaded a major effort to increase the capability of the armed forces to defend against biological agents. His military awards include the legion of Merit and the Distinguished Service Medal.
Following his military service, Russell joined Johns Hopkins University's School of Hygiene and Public Health as professor of international health and worked closely with the World Health Organization as special advisor to the Children's Vaccine Initiative. He was founding board member of the International AIDS Vaccine Initiative. After becoming professor emeritus in 1997, he served as an advisor to the Bill and Melinda Gates Foundation as well as several vaccine programs and was instrumental in creating the Malaria Vaccine Initiative.
Russell has served on numerous advisory boards of national and international agencies, including the Centers for Disease Control, National Institutes of Health and the Institute of Medicine, He served on the Boards of Directors of the International Vaccine Institute and the Aeras Foundation, and continues to be an integral part of the Albert B. Sabin Vaccine Institute. Following the anthrax attacks in 2001, Russell led a Department of Health and Human Services effort to develop and stockpile vaccines and other medical countermeasures against bioterrorism agents. He continues to work on the development of vaccines for the developing world.
Peter L. Thoren is Executive Vice President of Access Industries, Inc., a privately held, U.S.-based industrial group with strategic investments throughout the world. He is involved with numerous organizations focused on foreign policy and economics including The Center for National Policy, The Institute for Strategic Dialogue, the Council on Foreign Relations, and The Economic Club of New York. Before joining Access in 2001, Mr. Thoren held senior management positions with Salomon Inc and practiced law in New York. A native of Washington, D.C., Mr. Thoren received degrees from the University of North Carolina at Chapel Hill, the London School of Economics and Political Science and Georgetown University Law Center.
Michael Whitham is a founding partner of the law firm of Whitham, Curtis, Christofferson & Cook in Reston, VA. He has represented individuals, non-profit organizations, universities, small and large corporations, international organizations and universities on intellectual property matters for more than twenty years.
Mr. Whitham has helped craft license agreements involving patented technologies, copyrighted works, natural products, and technologies protected by trade secret. Mr. Whitham's practice includes the preparation and enforcement of a wide variety of contracts required by today's technology companies including confidentiality, supply, joint development, materials transfer, trademark licensing, copyright licensing, and employee agreements.
Mr. Whitham has prosecuted and defended patent, trademark, and copyright infringement actions, as well as actions involving theft of trade secrets in Federal District Courts, and has represented clients in Appeals to the Court of Appeals for the Fourth Circuit and the Federal Circuit.
Scott Wulfe is the Managing Partner of Vinson & Elkins LLP and is a member of the firm’s Management Committee. He maintains an active practice advising clients on mergers, acquisitions and divestitures, private equity investments and contests for corporate control. He has also represented many public companies, including several Fortune 500 companies, with respect to corporate governance advice and equity and debt offerings. Scott has substantial experience with clients in all aspects of the energy industry and has also achieved success for clients in a broad range of other industries, including financial services, airline and manufacturing. Chambers USA has described Scott as “client-oriented” and a “fabulous deal lawyer” who utilizes his “creativity and nonconfrontational style” in mergers and acquisitions and private equity transactions where his “proactive attitude” always “gets it right for clients.” Scott’s track record has also earned him recognition as one of The Best Lawyers in America® in the specialties of Corporate Law, Mergers & Acquisitions Law and Venture Capital Law and as a Super Lawyer in Texas in the Mergers & Acquisitions field.
Scott serves as a Trustee of The University of Texas Law School Foundation, a Trustee and Chair of the Risk Management & Insurance Committee of Texas Children’s Hospital, a Governing Director of the Houston Symphony and Board Member of the Alley Theatre.
Heloisa Sabin, who helped establish the Sabin Vaccine Institute in 1993, was unanimously elected Honorary Trustee on August 26, 2009. She has continuously championed the work and legacy of her late husband, Dr. Albert Sabin, by promoting the role of vaccines in eliminating needless deaths from preventable and treatable diseases.
Originally from Brazil, but currently residing in Washington, DC, Mrs. Sabin is a notable advocate for the vaccine and global health fields.
In Memoriam of the Founding Chairman
Dr. Shepherd was Founding Chairman of the Sabin Vaccine Institute and served on the Board of Trustees from 1993 to 2010. He also served as the Institute's President for eight years. Until 1993 he was Chairman and CEO of Armstrong Pharmaceuticals, Inc., which he founded as Aerosol Techniques in 1955.
A world-recognized expert on aerosol technologies, Dr. Shepherd spearheaded the development of the metered dose inhaler. He also led a successful effort to fund the nation's first research laboratory dedicated to aerosol pharmaceuticals at Columbia University College of Pharmacy and he is the author of Aerosols: Science and Technology, the first definitive text on the potential of aerosol medications.
Photo by Flickr user francois schnell/CC